CIA
CRNX

Cape Investment Advisory’s Crinetics Pharmaceuticals CRNX Stock Holding History

Cape Investment Advisory’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.2K Buy
+32
New +$1.19K ﹤0.01% 1309
2026
Q1 		– Sell
-31
Closed -$1.44K – 408
2025
Q4 		$1.44K Hold
31
– – ﹤0.01% 1149
2025
Q3 		$1.29K Hold
31
– – ﹤0.01% 721
2025
Q2 		$892 Buy
+31
New +$957 ﹤0.01% 1045

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cape Investment Advisory's CRNX Position: Q2 2026 in Review

Cape Investment Advisory opened a new position in Crinetics Pharmaceuticals (CRNX) in Q2 2026: 32 shares worth $1.2K. The stake represents ﹤0.01% of the portfolio and ranks #1309 among its holdings. This is a return to the name: Cape Investment Advisory previously reported a position in CRNX as recently as Q4 2025.

Cape Investment Advisory first reported a position in CRNX in Q2 2025 and has held it in 4 quarters since. The position peaked at $1.44K in Q4 2025. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Cape Investment Advisory held 32 shares of Crinetics Pharmaceuticals worth $1.2K as of Q2 2026.
  • Crinetics Pharmaceuticals was a new Cape Investment Advisory position in Q2 2026.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Cape Investment Advisory's portfolio in Q2 2026, its #1309 holding.
  • Cape Investment Advisory first reported a position in Crinetics Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • Cape Investment Advisory's Crinetics Pharmaceuticals position peaked at $1.44K in Q4 2025.
  • 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Cape Investment Advisory's 13F filing for Q2 2026, filed 23 Jul 2026.